Health plans’ use of real-world evidence for specialty drug coverage decisions is generally varied in terms of the number and type of studies cited, according to a recent article published by Wiley.
The authors, Ari Panzer et al., used data from the Tufts Medical Center Specialty Drug Evidence and Coverage Database to analyze coverage decisions by 17 large commercial health plans.
“Health plans varied with respect to the number and types of RWE studies they cited in their specialty drug coverage decisions,” the article states. “Plans cited RWE more often for some diseases than others, and cited more RWE for older drugs.”
To read the full article, click here. (Paid subscription required)